Its medical device sales fell short of Wall Street projections, causing J&J to plan an exit strategy for certain markets and stop selling some products under its orthopedic business.
Johnson & Johnson reported $2.2 billion in orthopedic sales in the third quarter of the year, up 3.4% from the same period last year. Its hip, knee, spine and sports medicine segments also saw year-over-year growth.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
